Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma.

EBioMedicine - 1 Jun 2018

Xiao Wenjing, Du Nan, Huang Taoyuan, Guo Jinan, Mo Xingkui, Yuan Tao, Chen Yong, Ye Ting, Xu Chunwei, Wang Wenxian, Wang Guoqiang, Cai Shangli, Chen Jing

Abstract excerpt

TP53 has been proved to be associated with cytotoxic T-cell induced apoptosis, however, the association between TP53 and the benefit of immunotherapy in melanoma has not been studied. In the present study, we examined the relationship between TP53 mutation and response to CTLA-4 blockade in metastatic melanoma by analyzing the data from one public cohort consisting of 110 patients with metastatic melanoma. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CTLA-4 Antigen
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fas Receptor

Share to Immunotherapy

Share to L-Lactate Dehydrogenase

Share to Melanoma

Share to Neoplasm Metastasis

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 29793878
DOI: 10.1016/j.ebiom.2018.05.019
PMCID: PMC6020711

Genes

FAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma.PMID 29793878Read ↗

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.Semantic proximity Read ↗

p53 Family in Resistance to Targeted Therapy of Melanoma.Semantic proximity Read ↗

Clinical impact of TP53 mutation status on survival outcomes in metastatic colorectal cancer.Semantic proximity Read ↗

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.Semantic proximity Read ↗

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.Semantic proximity Read ↗

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expressionSemantic proximity Read ↗

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.Semantic proximity Read ↗

Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung CancerSemantic proximity Read ↗

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.Semantic proximity Read ↗

P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferationSemantic proximity Read ↗

Chemotherapy-induced apoptosis in melanoma cells is p53 dependent.Semantic proximity Read ↗

Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.